31.1 C
New York
Saturday, June 13, 2026

Tag: 1

newssourceFORcompanyinformationcontent1marketreleases

Julian Barnes Named Laureate of the 2026 Fitzgerald Prize

British Novelist Honored at Hôtel Belles Rives for ‘Départ(s)’ at the Prize’s 15th Edition 
British Novelist Honored at Hôtel Belles Rives for ‘Départ(s)’ at the Prize’s 15th Edition

Julian Barnes Named Laureate of the 2026 Fitzgerald Prize

British Novelist Honored at Hôtel Belles Rives for ‘Départ(s)’ at the Prize’s 15th Edition 
British Novelist Honored at Hôtel Belles Rives for ‘Départ(s)’ at the Prize’s 15th Edition

Press Release: Sanofi’s Tzield approved in the US as the first disease-modifying therapy for patients recently diagnosed with stage 3 type 1 diabetes

FDA approves Sanofi's Tzield as first disease-modifying therapy for children 8-17 with stage 3 type 1 diabetes, delaying insulin decline based on PROTECT

Communiqué de presse : Le Tzield de Sanofi approuvé aux États-Unis comme première thérapie modificatrice de la maladie pour les patients récemment diagnostiqués avec...

La FDA approuve le Tzield de Sanofi comme première thérapie modificatrice pour enfants 8-17 ans atteints de diabète type 1 stade 3, retardant le déclin ins

WSE Investor News: If You Have Suffered Losses in Wise Group plc (NASDAQ: WSE), You Are Encouraged to Contact The Rosen Law Firm About...

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, continues to investigate potential securities claims on behalf of shareholders of Wise Group plc (NASDAQ: WSE) resulting from allegations that Wise Group plc may have issued materially misleading business information to the investing public.

ROSEN, A LEADING, LONGSTANDING, AND TOP RANKED FIRM, Encourages Commvault Systems, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action –...

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) --

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of securities of Commvault Systems, Inc. (NASDAQ: CVLT) between April 29, 2025 and January 26, 2026, inclusive (the “Class Period”), of the important July 17, 2026 lead plaintiff deadline.

Wells Fargo Foundation Provides $1 Million Grant to Expand Capital Access for Broward County Entrepreneurs

Ascendus to deploy $900,000 in loans and pair every dollar with hands-on coaching, from Prospera and other partners, supporting an estimated 160 local jobs...

Avicanna Announces Closing of Non-Brokered Private Placement

NOT FOR DISTRIBUTION TO UNITED STATES NEWSWIRE SERVICES OR FOR DISSEMINATION IN THE UNITED STATES. ANY FAILURE TO COMPLY WITH THIS RESTRICTION MAY CONSTITUTE A VIOLATION OF UNITED STATES SECURITIES LAWS

Heartland Express, Inc. Declares Regular Quarterly Dividend

NORTH LIBERTY, Iowa, June 12, 2026 (GLOBE NEWSWIRE) -- The Board of Directors of Heartland Express, Inc. (Nasdaq: HTLD) announced today the declaration of a regular quarterly cash dividend. The $0.02 per share dividend will be paid on July 6, 2026, to shareholders of record at the close of business on June 23, 2026. We currently estimate that a total of $1.6 million will be paid on the Company's approximate seventy-eight million shares of common stock. This is the Company's ninety-second consecutive quarterly cash dividend. With the payment of this dividend, the Company will have paid a total of $564.5 million in cash dividends, including four special dividends since the dividend program was implemented in the third quarter of 2003.

Atossa Therapeutics Announces Closing of Registered Direct Offering of up to $16.5 Million in Gross Proceeds

$4.5 million upfront with up to an additional $12 million of potential aggregate gross proceeds upon exercise in full of warrantsSEATTLE, June 12, 2026...

VVT Med Provides Update on Management Cease Trade Order

VANCOUVER, BC, June 12, 2026 /CNW/ - VVT Med Inc. (TSXV: VVTM) (the "Company" or "VVT") is providing an update with respect to its...

XORTX Announces Election to Voluntary Delist from the TSX Venture Exchange

CALGARY, Alberta, June 12, 2026 (GLOBE NEWSWIRE) -- XORTX Therapeutics Inc. ("XORTX" or the “Company”) (NASDAQ: XRTX | TSXV: XRTX | Frankfurt: ANU), a late-stage clinical pharmaceutical company focused on developing innovative therapies to treat gout and progressive kidney disease, announces that the Company has elected to voluntarily delist its common shares from the TSX Venture Exchange (“TSXV”). The Company will provide additional information on timing for the completion of the delisting of its common shares in a separate press release.

TAL Education Group Files Its Annual Report on Form 20-F

BEIJING, June 12, 2026 /PRNewswire/ -- TAL Education Group ("TAL" or the "Company") (NYSE: TAL), a smart learning solutions provider in China, today announced...

GraniteShares Announces Forward Splits

NEW YORK, June 12, 2026 (GLOBE NEWSWIRE) -- This announcement amends the effective date (or ex-date) previously circulated on June 08, 2026.

- A word from our sponsors -

spot_img

Newsletter Signup

Name(Required)
Email(Required)
Privacy(Required)
This field is for validation purposes and should be left unchanged.
HomeTags1

Explore

Press Releases

News & Opinion

Living

Others

Follow us

© Copyright 2025. BusinessPressWire® / 14 Wall Street New York City NY 10005 +1 888-502-0266 / Disclaimers